Biofrontera Inc. Marketing Campaign and Website for Ameluz Won 2022 PM360 Trailblazer Awards
WOBURN, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that PM360a publication aimed at marketing decision-makers in the pharmaceutical, biotechnology, diagnostics and medical device industries, awarded the previously nominated Ameluz Prize® marketing campaign, created by Biofrontera Inc. with Elevate Healthcare, awarded “Revival/Revitalization of the Year” and “Professional Website/Online Initiative of the Year”. These awards were announced on the 14e The annual Trailblazer Awards took place on September 22, 2022 in New York City, where they also recognized previously announced Trailblazer Brand Champion in Dermatology, Leslie Hopkins, Associate Director of Marketing at Biofrontera Inc. The winners will be featured in the issue of October from PM360 and at www .pm360online.com.
Ameluz de Biofrontera® The marketing campaign, developed in conjunction with healthcare-focused branding agency Elevate Healthcare Marketing, was a creative call to action highlighting the threat of actinic keratoses (AKs). Titled “Danger Lies Beneath the Surface,” the campaign featured images of sharks and aims to raise awareness of the danger associated with visible and invisible AKs. It also positions Ameluz® more BF-RhodoLED® (Ameluz-PDT) as the only photodynamic therapy (PDT) with field treatment approval that enables healthcare professionals to protect patients from the risks posed by premalignant AK fields.
“We are very proud of our marketing team and the collaboration with Elevate Healthcare. Their efforts are not only recognized by the marketing industry, but are also reflected in the improved revenue we generate. The launch of the Ameluz website was a strategic step in a larger initiative to improve medical support and build brand awareness. Educating the industry on the importance of field therapy and the efficacy of our products is a critical part of our market expansion and business strategy which we believe will increase the use of PDT, especially among patients with 15 or more AK lesions,” said Erica Monaco, President and CEO of Biofrontera Inc.
“Leslie has also been a true champion of the brand not only for PM360 but also for us, having led the team in the relaunch of the Ameluz campaign. She inspired rethinking of the AK treatment landscape, challenged perceptions of PDT and pushed for a stronger creative vision for the campaign to disrupt the market and reinvigorate the brand,” added Mark Baldyga, VP -President of Sales and Marketing at Biofrontera Inc.
Since 2009, the PM360 Trailblazer Awards have recognized outstanding achievement and innovation in healthcare marketing. Each year, nominations are judged by PM360’s Editorial Advisory Board, a cross-section of industry experts. Initiatives are selected in 16 distinct categories. Silver and Gold winners were selected in each category for their ability to stand out in a complex and ever-changing healthcare environment, and were judged on content, format, success in reaching target audience and overall quality.
“Marketers increasingly face new challenges in reaching their audiences with messages that resonate, whether it’s an oversaturated market, rising consumer expectations or even a global pandemic. “, says Anna Stashower, CEO and publisher of PM360. “But each of our Initiative Award winners is a great example of how to overcome these challenges through creativity, ingenuity and a drive to better understand healthcare professionals, patients and payers in order to better deliver a experience that matches their wants and needs.”
The Ameluz marketing campaign has also been previously recognized by other publications, including winning a Gold 2022 Excellence Award from the Communicator Awards, a leading independent industry international awards program recognizing excellence in communication, championing effective and meaningful work.
PM360 is the premier go-to magazine for marketing decision makers in the pharmaceutical, biotechnology, diagnostics and medical device industries. Published monthly, PM360 is the only journal focused on providing the full range of practical information necessary for product managers and pharmaceutical marketing professionals to succeed in the complex and highly regulated environment of healthcare.
The journal’s focused and insightful editorial focuses on issues that have a direct impact on critical decision-making, including planning and implementing cutting-edge strategies, trends, the latest technological advances, the branding/marketing, advertising/promotion, patient/professional education, sales, market research. , public relations and leadership. Additionally, the “360” in the title signifies the breadth of this critical and practical information with personal and professional information for enjoyable and stimulating reading.
By providing the full circle of enriching content, PM360 is truly an indispensable tool for keeping busy and productive marketing professionals at the top of their game.
About Biofrontera Inc.
Biofrontera Inc. is a US-based biopharmaceutical company that markets a portfolio of pharmaceutical products for the treatment of dermatological conditions with an emphasis on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are precancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.
Certain statements contained in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the company’s business and marketing strategy, future operations and activities, the expansion potential of the Ameluz label®market presence and position of Ameluz® and ongoing clinical trials conducted by our licensing partners and the future impact of these trials on the Ameluz market®. We have based these forward-looking statements on our current expectations and projections regarding future events, however, actual results or events could differ materially from the plans, intentions and expectations disclosed or implied by the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, including, but not limited to, the impact of extraordinary external events, such as the current COVID-19 pandemic; any change in the Company’s relationship with its licensors; the ability of the Company’s licensors to fulfill their obligations to the Company in a timely manner; the Company’s ability to achieve and maintain profitability; whether the current global supply chain disruptions will impact the Company’s ability to obtain and distribute its licensed products; changes in healthcare provider practices, including any changes in coverage, reimbursement and pricing for procedures using the Company’s licensed products; the uncertainties inherent in initiating and conducting clinical trials; availability and timing of clinical trial data; whether the results of previous clinical trials or trials of Ameluz® in combination with BF-RhodoLED® in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and marketing authorization applications; if the market opportunity for Ameluz® in combination with BF-RhodoLED® is in line with the Company’s expectations; the Company’s ability to complete the transition to a public company; the Company’s ability to retain and hire key personnel; the sufficiency of cash resources and the need for additional financing and other factors that may be disclosed in the Company’s filings with the SEC, which may be obtained at the SEC’s website at www. sec.gov. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not intend to update these forward-looking statements and expressly disclaims any obligation to update the information contained in this press release, except as required by law.
Anke zur Mühlen
+1 781 486 1539
LHA Investor Relations
Tirth T. Patel
+1 212 201 6614
# # #